| Literature DB >> 34739619 |
Khadija El Aoufy1, Maria Ramona Melis2, Silvia Bellando Randone2, Jelena Blagojevic2, Francesca Bartoli2, Ginevra Fiori2, Francesca Nacci2, Maria Letizia Conforti2, Laura Cometi2, Cosimo Bruni2, Martina Orlandi2, Alberto Moggi-Pignone3, Laura Rasero4, Serena Guiducci2, Marco Matucci-Cerinic2,5.
Abstract
Patients and health workers were at high risk of infection during the Sars-Cov-2 pandemic lockdown. For this reason, other medical and clinical approaches such as Telemedicine were necessary. Despite Telemedicine was born before COVID-19, the pandemic was the opportunity to accelerate a process already underway for at least a decade and to blow all the barriers away. Our aim is to describe the experience of Telemedicine during and immediately after the first lockdown to assure the follow-up in a 'virtual' outpatient clinic dedicated to Rheumatic and Musculoskeletal Diseases (RMDs) and to give an overview of Telemedicine in the rheumatology field. We retrospectively evaluated the patient flow to our rheumatology division from March to September 2020 and, in accordance with local restrictions, three periods were selected. In the 1st period, 96.96% of the outpatient clinic cases were shifted to Telemedicine; these decreased to 52.45% in the 2nd period, while the 3rd period was characterized by the return of the patients at the clinic (97.6%). Diagnostic procedures were postponed during the 1st period, reduced drastically during the 2nd and performed regularly during the third period. Intravenous infusions were maintained as much as possible during the three periods, to assure therapeutic continuity. Shifting stable patients to Telemedicine has the potential to allow continuity of care, while reducing the risk of contagion during a pandemic. In the next future, the integration of Telemedicine as standard of care for specific clinical applications might assure assistance for RMDs patients also in non-pandemic conditions.Entities:
Keywords: COVID-19; Rheumatic and Musculoskeletal Diseases; Sars-Cov-2; Telemedicine
Mesh:
Year: 2021 PMID: 34739619 PMCID: PMC8569841 DOI: 10.1007/s10067-021-05975-2
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980
Aspects of disease manageable and not manageable with telemedicine
| Aspects of RMDs manageable with Telemedicine | Aspects of RMDs not fully manageable with Telemedicine |
|---|---|
• Continued patient care during pandemic events • Regular follow up for stable patients • Patient education • Clinimetry/Telemetry • Patient counseling • Detection of urgent problems • Drug Adherence and patients’ compliance • Detection of drug-related adverse effects • Dealing with general practitioners • Renewal of the therapeutic prescriptions | • First consultation of complex cases • Physical/joint examination • Thorough evaluation of disease flare • Management of digital lesions |
Fig. 1The percentage of visits and Telemedicine during the SARS-CoV-2 pandemic from February 2020 to September 2020